Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 3/20 | 0.43 |
| ▸ | PPARA | Q07869 | 3/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 7/20 | 0.41 |
| ▸ | MME | P08473 | 1/20 | 0.40 |
| ▸ | ACE | P12821 | 1/20 | 0.40 |
| ▸ | CPA1 | P15085 | 1/20 | 0.40 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.40 |
| ▸ | PLAT | P00750 | 3/20 | 0.40 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.39 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21944801 | 0.87 | MAOB (0.43) | MAOBPLATNR4A2FFAR1MRGPRX4 | |
| SCHEMBL21945001 | 0.83 | SRD5A2 (0.50) | PPARDPPARAPPARGMAOBNR4A2 | |
| SCHEMBL21945011 | 0.81 | MAOB (0.50) | PPARAMAOBMMEACECPA1 | |
| Bromide SCHEMBL28540140 | 0.74 | MAOB (0.58) | PPARDPPARAMAOBNR4A2FFAR1 | |
| SCHEMBL21945004 | 0.72 | SRD5A2 (0.43) | MAOBNR4A2FFAR1 | |
| SCHEMBL12584946 | 0.72 | MAOB (0.53) | PPARDPPARAMAOBNR4A2 | |
| SCHEMBL13960103 | 0.70 | MAOB (0.54) | MAOBMMEACECPA1ACE2 | |
| SCHEMBL12424195 | 0.70 | MAOB (0.54) | MAOBNR4A2 | |
| SCHEMBL6690271 | 0.68 | RAB9A (0.54) | PPARDPPARAMAOBPLATNR4A2 | |
| SCHEMBL21944881 | 0.68 | PPARD (0.46) | PPARDPPARAPPARGMAOBNR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10626095-B2 | Cyanotriazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10626095-B2 | Cyanotriazole compounds | CS, PC, ACAT1 | PPARD 428/4885PPARA 284/4885PPARG 269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.